|Bid||256.50 x 10000|
|Ask||256.70 x 10000|
|Day's Range||257.50 - 257.50|
|52 Week Range||162.00 - 261.80|
|Beta (5Y Monthly)||1.01|
|PE Ratio (TTM)||10.33|
|Earnings Date||Feb. 09, 2022 - Feb. 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||334.29|
Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.
Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.
BURLINGTON, N.C., December 03, 2021--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. The addition of Toxikon to Labcorp Drug Development bolsters Labcorp’s strong nonclinical development portfolio, and creates a strategic footprint for the company to partner with pharmaceutical and biotechnology clients in the Boston, Mass.